Lotiglipron
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Lotiglipron
- Molecular weight
- 575.07
- Structure (SMILES)
- C[C@]1(c2ccc(Cl)cn2)Oc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)c2O1
- Formulation B (PF-07081532 80 mg)
- formulation b pf 07081532 80 mg
- lotiglipron
- Lotiglipron
- lotiglipron [INN]
- LOTIGLIPRON [USAN]
- Lotiglipron [WHO-DD]
- lotiglipron inn
- lotiglipron usan
- lotiglipron who dd
- pf 07081532
- Pf-07081532
- PF-07081532
- CAS registry numbers
- 2401892-75-7
- ChEMBL ID
- CHEMBL5314631
- InChIKey
- SVPYZAJTWFQTSM-UGDMGKLASA-N
- PubChem compound IDs
- 146609022
- FDA ingredient codes (UNII)
- YI10W1K93A
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- lotiglipron
- Type
- Synthetic organic
- Drug name stem
- -glipron
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 9.02
- Affinity units
- pEC50
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- HP_0001513
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 2
- NCT04305587
- NCT05158244
- NCT05478603
- NCT05671653
- NCT05677867
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 1
- Polar surface area
- 98.94
- Calculated partition coefficient (ALogP)
- 5.6
- Calculated partition coefficient (XLogP)
- 1.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 7
- Heavy atoms
- 41
- Molecular formula
- C31H31ClN4O5
- Monoisotopic mass
- 574.1982978
- Natural product
- No
- Recorded assays
- 3
- Active assays
- 3
Active assay types
- Confirmatory
Related records
Trials (11)
- A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction
- A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
- A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults
- A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
- A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
- A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men
- A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
- Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
- Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
- Study of Single Ascending Doses of PF-07081532 in Healthy Adult Participants
- Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
In development for (3)
- Liver disorder Phase 1
- Obesity disorder Phase 1
- Type 2 diabetes mellitus Phase 1